SCHEMBL20239170

SCHEMBL20239170

CCc1cnc(NCc2cc(N)nc(Oc3ccc(CS(N)(=O)=O)cc3)c2)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 2/20 0.35
CA1 P00915 5/20 0.35
CA2 P00918 5/20 0.35
CA9 Q16790 5/20 0.35
CYP1A2 P05177 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
VNN1 O95497 2/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
NCF1 P14598 1/20 0.33
CA12 O43570 1/20 0.32
MPO P05164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20239229 0.99 DGAT2 (0.49) DGAT2SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL20239319 0.89 DGAT2 (0.60) DGAT2SMN1; SMN2RAB9AALDH1A1CA1
SCHEMBL20239275 0.86 CA1 (0.44) DGAT2SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL20239218 0.85 DGAT2 (0.47) DGAT2RAB9ANPC1ALDH1A1CA1
SCHEMBL20239230 0.85 DGAT2 (0.47) DGAT2SMN1; SMN2RAB9ANPC1CA1
SCHEMBL20239337 0.85 DGAT2 (0.58) DGAT2SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL20259239 0.85 SMN1; SMN2 (0.38) DGAT2SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL20239140 0.83 DGAT2 (0.58) DGAT2SMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL20239261 0.80 DGAT2 (0.51) DGAT2SMN1; SMN2RAB9AALDH1A1CYP1A2
SCHEMBL20239328 0.77 DGAT2 (0.47) DGAT2CA1CA2CA9VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885SMN1; SMN2 4828/4885RAB9A 1170/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885SMN1; SMN2 4835/4885RAB9A 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.